Exclusions from this analysis were made if patients had unknown clinical outcome or smoking status (n=41), or provided insufficient information on other critical prognostic factors (n=3).
Exclusions from this analysis were due to death (n = 7), withdrawal (n = 6), loss to follow up (n = 5), incomplete 36-month BSID-II (n = 39) due to administration errors, home-visit data unavailable (n = 1), or another reason (n = 1).
This resulted in the exclusion from the analysis of the following number of subjects: co-trimoxazole (1 1); other antibiotics 14 (1414).
This was sensitive to the exclusion from the analysis of studies with undeclared funding.
The main limitations of this study were the lack of a control group and the exclusion from the analysis of 12 patients who failed to achieve glycemic control after 2 weeks' CSII treatment.
The incidents leading to the exclusion from the analysis had been caused by either human errors consisting prematurely stopped measurements or were technical in nature, such as dosimeter breakdown or failure necessitating repair or replacement.
This is equally true for the cases where insufficient detailed data forced exclusion from the analysis.
Reasons for exclusion from the analysis set are presented in Fig. 1.
Exclusion from the analysis was lack of anthropometry measurements or SES data.
Their exclusion from the analysis, therefore, is not expected to introduce bias.
